Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC - Takeaways - MDSpire

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • By

  • Lorenzo De Sanctis

  • Riccardo Ray Colciago

  • Giulia Rossano

  • Matteo Ferrari

  • Matteo Mombelli

  • Ilenia Manno

  • Federica Ferrario

  • Sara Saufi

  • Valeria Faccenda

  • Denis Panizza

  • Gaia Passarella

  • Stefania Canova

  • Diego Luigi Cortinovis

  • Stefano Arcangeli

  • May 25, 2026

  • 0 min

Share

  • 1

    Progression-directed radiation therapy (PDRT) improved event-free survival (EFS) in patients with oligoprogressive non-small cell lung cancer (NSCLC).

  • 2

    The study included 87 NSCLC patients, with a median follow-up of 14 months and a one-year actuarial EFS rate of 52.1%.

  • 3

    PDRT was associated with a median time to next treatment of 8 months and a median EFS of 5 months, indicating effective disease control.

  • 4

    Multivariate analysis showed that PDRT targeting the primary tumor and achieving a complete response improved EFS significantly.

  • 5

    The findings suggest PDRT may delay systemic treatment initiation in oligoprogressive NSCLC, warranting further prospective studies.

Original Source(s)

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • by Lorenzo De Sanctis, Riccardo Ray Colciago, Giulia Rossano, Matteo Ferrari, Matteo Mombelli, Ilenia Manno, Federica Ferrario, Sara Saufi, Valeria Faccenda, Denis Panizza, Gaia Passarella, Stefania Canova, Diego Luigi Cortinovis, Stefano Arcangeli

  • May 25, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer